drugset / Trial / NCT03742804
Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The overall goal of this study is to evaluate the safety and immunogenicity of repeat-dose intratumoral G100 administration in patients with Cutaneous T Cell Lymphoma (CTCL) alone (Part 1) and following standard local radiation therapy or topical nitrogen mustard application (Part 2). Plaque, patch, or tumor lesions of CTCL may be injected. Disease will be assessed in all sites, including skin, nodes, and blood.
Timeline
- Start
- 2019-06
- Primary completion
- 2019-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glucopyranosyl Lipid A | Unknown | — | Other |